Adiponectin Peptides Reduce Amyloid Beta Without Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for degenerative neurological disorders, such as Alzheimer's disease, lack effective compositions that can reduce β-amyloid precursor protein and amyloid beta protein expression while enhancing cognitive function without cytotoxicity.
Innovation Solution
A composition containing adiponectin receptor-activating novel peptides, specifically peptides with amino acid sequences SEQ ID NOS: 1 to 10, which are administered to subjects to reduce APP and Aβ protein levels and improve memory and cognitive functions without causing cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for neurological disorders are used, then some symptomatic relief may be achieved, but they cannot reduce APP and Aβ protein expression and may cause cytotoxicity
Solution Approach 1:
The patent uses adiponectin receptor-activating peptides that specifically modulate the biological activity of adiponectin receptors, changing the physiological parameters of protein expression and neuronal function without triggering cytotoxic responses. This selective parameter modulation achieves therapeutic effects while avoiding harmful side effects.
Solution Approach 2:
The adiponectin receptor-activating peptides act as intermediary substances that mediate between the administration system and the target proteins (APP and Aβ). These peptides reduce harmful protein aggregation through indirect mechanisms involving adiponectin receptor activation, rather than directly attacking the proteins, thereby avoiding cytotoxicity.
2Reliability
If current Alzheimer's treatments are administered, then some cognitive symptoms may be managed, but cognitive and memory functions are not enhanced
Solution Approach 1:
The adiponectin receptor-activating peptides exhibit multi-functionality, simultaneously achieving multiple therapeutic effects: reducing APP expression, reducing Aβ protein levels, and enhancing cognitive and memory functions. This single agent addresses multiple aspects of Alzheimer's pathology and symptomatology.
3Measurement precision
If diagnostic methods for degenerative neurological disorders are used, then some symptoms can be identified, but accurate diagnosis is difficult due to common clinical symptoms across various disorders
Solution Approach 1:
The patent employs therapeutic agents with measurable effects on specific biomarkers (APP and Aβ protein expression levels). By monitoring changes in these protein expressions and cognitive function metrics before and after treatment, clinicians can obtain feedback that helps differentiate between various neurological disorders and assess treatment response, thereby improving diagnostic accuracy.
Data Source
Figure 1
Figure 2(A)~2(C)
Figure 3
AI summary
Provided is a composition for the prevention, improvement, or treatment of a neurological disorder, the composition including an adiponectin receptor-activating novel peptide as an active ingredient. The adiponectin receptor-activating novel peptide is a peptide consisting of 5 amino acids, and when the adiponectin receptor-activating novel peptide is administered to Alzheimer's model mice, the mice's behavioral changes show that memory and cognitive functions are significantly increased, and APP and amyloid beta (Aβ) proteins are significantly reduced, cytotoxicity does not occur, the proliferation rate of neurons is increased, and cell death is inhibited.